Bone Biologics Corporation, a company specializing in orthobiologic products for spine fusion markets, has successfully closed a public offering, raising $5.0 million. The offering included 1,250,000 shares of common stock, Series D warrants to purchase an equal number of shares, and Series E short-term warrants, all priced at $4.00 per share. The Series D warrants are exercisable immediately and expire in five years, while the Series E warrants also have immediate exercisability and expire in 18 months. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The funds raised will support clinical trials, patent portfolio maintenance, and general corporate purposes. If all warrants are exercised, additional proceeds could reach $10.0 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。